Should You Buy UNH Stock Because Its Cash Runs Ahead Of Its Profit?

UnitedHealth (UNH) has spent the past year repairing margins rather than chasing growth. The shares rebounded well ahead of any actual margin recovery: up about 38% over the past six months, though down about 6% over the past three, and still behind the S&P 500 over the past twelve months, 12.2% for the stock against 18.6% for the index. What argues for owning them now shows up in cash running ahead of reported profit.

Why Is UnitedHealth Still Generating Cash On Thinner Margins?

The trailing numbers are worse than a year ago. Operating margin over the trailing twelve months is 4.8%, down from 7.3%. In the second quarter of 2026, management reported pressure in commercial benefits and better results in Medicare Advantage.

The cash did not follow the margin down. Free cash flow ran about 167% of reported net income over the trailing twelve months, so the business collects more cash than it books as profit. Operating cash flow in the second quarter of 2026 was roughly $11 billion, about 1.9 times net income, which the company attributes to strong earnings and the timing of government payments. Even after smoothing out quarterly timing noise and capital spending, trailing free cash flow remained robust at 167% of net income.

Some of the margin trade-off is deliberate. Management priced Medicare Advantage for margin instead of membership, and expects enrollment there to fall by about 1.1 million across 2026, with Medicare margins finishing the year above 3%.

What Is UnitedHealth Doing With The Money?

Direct shareholder return is the clearest use. Alongside a regular dividend that returned $2.1 billion in the second quarter alone, the company now expects full-year share repurchases of at least $5 billion, up from $2.5 billion guided at the start of the year. What remains after shareholder distributions goes into strengthening the balance sheet and funding operational automation. Debt to capital was 41.2% at the end of the second quarter of 2026, down from 44.1% a year earlier.

Meanwhile, operational spending is focused on automation—ambient documentation tools reach 70% of Optum Health’s employed clinicians, and the company has committed to cutting prior authorization volume by 30% by the end of 2026.

Can UnitedHealth Outrun Its Commercial Cost Problem?

Not yet, and management does not claim otherwise. Commercial medical cost trends are running modestly above the 11% already assumed, pushed there by the No Surprises Act arbitration process and by heavier provider coding. That process is adding about 50 basis points of incremental trend in 2026, and now totals at least 100 basis points of cost. Full commercial margin recovery has now moved past 2027.

The outlook has gone up anyway. Full-year 2026 adjusted earnings guidance moved from more than $18.25 a share in April to $19.50 to $20 in July. Part of the increase came from reserve development: the second quarter’s medical care ratio included $860 million of net favorable prior period development, the majority of it in-year.

So the cash does not cure the cost trend. At 24.2 times trailing earnings, inside a ten-year range of 13.3 to 37.7, the price is not the argument here. What the cash buys is time for a multi-year balance-sheet and operational repair. The test through the rest of 2026 is whether that guidance range moves up again. Our screen of companies whose guidance keeps climbing tracks that.

Would You Buy UnitedHealth And Wait?

Perhaps, but for the cash rather than for a quick margin recovery. A screen will tell you whether the outlook is still improving. It cannot tell you how long you are willing to wait. If you would rather not make that call name by name, the Trefis High Quality Portfolio picks its holdings by rule. That portfolio has a track record of outpacing the three major indices.